How to improve cervical cancer screening in Switzerland?

Swiss Medical Weekly

Volumn 142, Issue , 2012, Pages

  Petignat, Patrick ^a   Untiet, Sarah ^a   Vassilakos, Pierre ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b WHO Collaborating Centre in Education and Research in Human Reproduction   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; FALSE POSITIVE RESULT; FEMALE; HUMAN; LETTER; MORBIDITY; NONHUMAN; PAPANICOLAOU TEST; PREDICTIVE VALUE; SCREENING TEST; SWITZERLAND; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; EARLY DIAGNOSIS; METHODOLOGY; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; SWITZERLAND; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84866267039     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2012.13663     Document Type: Letter

References (22)

1. Bouchardy C, Fioretta G, Raymond L, Vassilakos P. Age differentials in trends of uterine cervical cancer incidence from 1970 to 1987 in Geneva. Revue d'epidemiologie et de sante publique. 1990;38:261-2. (Pubitemid 20270386)
2. SGGG AGZ. Guideline zum Vorgehen bei suspektem und positivem zytologischen Abstrich der Cervix Uteri (überarbeitete Fassung, Version 2.4.). Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe; 2004. p. 3-27.
3. Cullati S, Charvet-Berard AI, Perneger TV. Cancer screening in a middle-aged general population: factors associated with practices and attitudes. BMC Public Health. 2009;9:118.
4. EKIF. Directive and recommendation no. 21: HPV vaccination recommendation 2007.
5. Bouchardy C, Pury P, Raymond L. Le cancer en suisse: principales données épidémiologiques (2e partie). Bull Suisse Cancer. 2005;2:121-8.
6. Petignat P, Bouchardy C, Sauthier P. Cervical cancer screening: current status and perspectives. Rev Med Suisse. 2006;2:1308-9, 11-2.
7. Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for cervical cancer: a decision analysis for the US preventive services task force. Rockville (MD)2011.
8. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007;197:356 e1-6.
9. Van Hentenryck M, Noel JC, Simon P. Obstetric and neonatal outcome after surgical treatment of cervical dysplasia. European journal of obstetrics, gynecology, and reproductive biology. 2012;162:16-20.
10. Adab P, McGhee SM, Yanova J, Wong CM, Hedley AJ. Effectiveness and efficiency of opportunistic cervical cancer screening: comparison with organized screening. Medical care. 2004;42:600-9.
11. Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br J Cancer. 2005;93:575-81. (Pubitemid 43080002)
12. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095-101. (Pubitemid 44116919)
13. Bulk S, Bulkmans NW, Berkhof J, Rozendaal L, Boeke AJ, Verheijen RH, et al. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer. 2007;121:361-7. (Pubitemid 46917706)
14. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764-72. (Pubitemid 350137476)
15. Naucler P, RydW, Tornberg S, Strand A,Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589-97. (Pubitemid 47598401)
16. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-88. (Pubitemid 47598400)
17. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249-57.
18. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.
19. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-9. (Pubitemid 41417924)
20. Almonte M, Sasieni P, Cuzick J. Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines. Best practice & research Clinical obstetrics & gynaecology. 2011;25:617-29.
21. Petignat P, Vassilakos P. Is it time to introduce HPV self-sampling for primary cervical cancer screening? J Natl Cancer Inst. 2012.
22. Petignat P, Faltin DL, Bruchim I, Tramer MR, Franco EL, Coutlee F. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol. 2007;105:530-5. (Pubitemid 46590347)